These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3167 related articles for article (PubMed ID: 7074548)

  • 1. An analysis of skin tests and their relationship to recurrence and survival in stage III and stage IV melanoma patients.
    Lee ET; Ishmael DR; Bottomley RH; Murray JL
    Cancer; 1982 Jun; 49(11):2336-41. PubMed ID: 7074548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
    Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
    J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.
    Zörnig I; Halama N; Lorenzo Bermejo J; Ziegelmeier C; Dickes E; Migdoll A; Kaiser I; Waterboer T; Pawlita M; Grabe N; Ugurel S; Schadendorf D; Falk C; Eichmüller SB; Jäger D
    Int J Cancer; 2015 Jan; 136(1):138-51. PubMed ID: 24839182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
    Feun LG; Gutterman J; Burgess MA; Hersh EM; Mavligit G; McBride CM; Benjamin RS; Richman SP; Murphy WK; Bodey GP; Brown BW; Mountain CF; Leavens ME; Freireich EJ
    Cancer; 1982 Oct; 50(8):1656-63. PubMed ID: 7116298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma.
    Bystryn JC; Oratz R; Roses D; Harris M; Henn M; Lew R
    Cancer; 1992 Mar; 69(5):1157-64. PubMed ID: 1739915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
    Balch CM; Soong SJ; Murad TM; Smith JW; Maddox WA; Durant JR
    J Clin Oncol; 1983 Feb; 1(2):126-34. PubMed ID: 6668496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNCB reactivity and prognosis in 419 patients with malignant melanoma.
    Camacho ES; Pinsky CM; Braun DW; Golbey RB; Fortner JG; Wanebo HJ; Oettgen HF
    Cancer; 1981 May; 47(10):2446-50. PubMed ID: 7272900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
    Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS
    J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization.
    de Gast GC; The TH; Schraffordt Koops H; Huiges HA; Oldhoff J; Nieweg HO
    Cancer; 1975 Oct; 36(4):1289-97. PubMed ID: 1175127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in 1,521 melanoma patients with distant metastases.
    Barth A; Wanek LA; Morton DL
    J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of leukocyte-dependent antibody activity in melanoma patients.
    Hersey P; Edwards A; Murray E; McCarthy WH; Milton GW
    J Natl Cancer Inst; 1983 Jul; 71(1):45-53. PubMed ID: 6575208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-metastatic stage IV nasopharyngeal carcinoma patients: analysis of the pattern of relapse and survival.
    Ozyar E; Gurkaynak M; Yildiz F; Atahan IL
    Radiother Oncol; 2004 Jul; 72(1):71-7. PubMed ID: 15236877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic significance of recall antigen testing in melanoma patients.
    Saltz J; Buckley CE; Cox E; Seigler HF
    Am J Med Sci; 1987 Nov; 294(5):287-93. PubMed ID: 3425578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia as a prognostic factor among patients with stage III melanoma.
    Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
    Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phytohemagglutinin skin tests in cancer patients.
    Zuckerman KS; LoBuglio AF
    Cancer; 1977 Jun; 39(6):2355-61. PubMed ID: 266970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin, clinical Stage I.
    Johnson OK; Emrich LJ; Karakousis CP; Rao U; Greco WR
    Cancer; 1985 Mar; 55(5):1107-17. PubMed ID: 3967194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early-stage non-Spitzoid cutaneous melanoma in patients younger than 22 years of age at diagnosis: long-term follow-up and survival analysis.
    Stanelle EJ; Busam KJ; Rich BS; Christison-Lagay ER; Dunkel IJ; Marghoob AA; Halpern A; Coit DG; La Quaglia MP
    J Pediatr Surg; 2015 Jun; 50(6):1019-23. PubMed ID: 25819019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 159.